Inventor · disambiguated record
Torsten Dreier
Also filed as: DREIER TORSTEN
29 granted patents·19 pending applications·297 citations·filing 2001–2025
97Inventor score
Top patents by PatentIndex Score
48 records- 0194US9765149B2Antibodies to CD70ARGEN-X N V·Filed 2014·Granted Sep 19, 2017·24 cites·22 claims
- 0294US9765148B2Antibodies to CD70SILENCE KAREN·Filed 2012·Granted Sep 19, 2017·32 cites·13 claims
- 0394US8834882B2Antibodies to CD70SILENCE KAREN·Filed 2013·Granted Sep 16, 2014·30 cites·12 claims
- 0493US9315576B2Antigen binding polypeptidesARGEN X BV·Filed 2015·Granted Apr 19, 2016·5 cites·12 claims
- 0593US8524231B2Antigen binding polypeptidesDREIER TORSTEN·Filed 2011·Granted Sep 3, 2013·19 cites·32 claims
- 0693US8444976B2Antigen binding polypeptidesDREIER TORSTEN·Filed 2009·Granted May 21, 2013·12 cites·19 claims
- 0792US11505585B2FcRn antagonists and methods of useargenx BV·Filed 2017·Granted Nov 22, 2022·7 cites·10 claims
- 0892US10316073B2FCRN antagonists and methods of useARGENX BVBA·Filed 2014·Granted Jun 11, 2019·20 cites·10 claims
- 0992US9221918B2Antigen binding polypeptidesARGEN X BV·Filed 2015·Granted Dec 29, 2015·5 cites·4 claims
- 1091US9540437B2Humanized antibodiesARGEN-X N V·Filed 2014·Granted Jan 10, 2017·8 cites·49 claims
- 1191US9346891B2Antigen binding polypeptidesARGEN X BV·Filed 2015·Granted May 24, 2016·5 cites·20 claims
- 1291US7332168B2Composition for the elimination of autoreactive B-cellsMICROMET AG·Filed 2001·Granted Feb 19, 2008·42 cites·2 claims
- 1390US9428580B2Antigen binding polypeptidesDREIER TORSTEN·Filed 2011·Granted Aug 30, 2016·5 cites·28 claims
- 1489US8637027B2Anti c-Met antibodiesHULTBERG ANNA·Filed 2011·Granted Jan 28, 2014·12 cites·21 claims
- 1588US12240875B2Use of FCRN antagonists for treatment of generalized myasthenia gravisargenx BV·Filed 2018·Granted Mar 4, 2025·3 cites·21 claims
- 1688US7323440B2De-immunized MOG (poly)peptide constructsMICROMET AG·Filed 2003·Granted Jan 29, 2008·41 cites·8 claims
- 1787US10793627B2GARP-TGF-β 1 IGG antibodiesARGENX BVBA·Filed 2019·Granted Oct 6, 2020·2 cites·1 claims
- 1885US12202900B2Compositions and methods for treating immune thrombocytopeniaargenx BV·Filed 2019·Granted Jan 21, 2025·4 cites·14 claims
- 1985US9926364B2Chimeric human-llama antigens and methods of useARGEN X N V·Filed 2012·Granted Mar 27, 2018·5 cites·18 claims
- 2083US11434298B2Antibodies to CD70argenx BV·Filed 2019·Granted Sep 6, 2022·1 cites·11 claims
- 2183US11072665B2Antibodies to CD70ARGENX BVBA·Filed 2015·Granted Jul 27, 2021·2 cites·39 claims
- 2283US9688773B2C-Met antibody combinationsHULTBERG ANNA·Filed 2011·Granted Jun 27, 2017·5 cites·20 claims
- 2382US10875914B2Nucleic acids encoding GARP-TGF-beta 1 antibodiesARGENX BVBA·Filed 2019·Granted Dec 29, 2020·1 cites·18 claims
- 2482US9884917B2Anti c-Met antibodiesARGEN X N V·Filed 2013·Granted Feb 6, 2018·4 cites·9 claims
- 2581US2024158492A1Il-6 binding moleculesargenx BV·Filed 2023·Application pending·0 cites
- 2681US2023265201A1Antibodies to cd70argenx BV·Filed 2022·Application pending·0 cites
- 2778US10479829B2GARP-TGF-beta 1 antibodiesARGENX BVBA·Filed 2018·Granted Nov 19, 2019·1 cites·16 claims
- 2875US11827701B2IL-6 binding moleculesargenx BV·Filed 2021·Granted Nov 28, 2023·0 cites·18 claims
- 2975US10183995B2IL-6 binding moleculesARGEN X N V·Filed 2013·Granted Jan 22, 2019·2 cites·36 claims
- 3073US2025215090A1Compositions and methods for treating immune thrombocytopeniaargenx BV·Filed 2024·Application pending·0 cites
- 3172US11117959B2IL-6 binding moleculesARGENX BVBA·Filed 2019·Granted Sep 14, 2021·0 cites·15 claims
- 3270US2022275035A1Fcrn antagonists and methods of useargenx BV·Filed 2022·Application pending·0 cites
- 3367US10676535B2Anti c-Met antibodiesARGENX BVBA·Filed 2017·Granted Jun 9, 2020·0 cites·10 claims
- 3467US2021324061A1Garp-tgf-beta antibodiesARGENX BVBA·Filed 2020·Application pending·0 cites
- 3563US2015064182A1Stabilized single domain antibodiesABLYNX NV·Filed 2014·Application pending·0 cites
- 3663US2016319040A1Antigen binding polypeptidesARGEN-X B V·Filed 2016·Application pending·0 cites
- 3762US2009238829A1Stabilized single domain antibodiesABLYNX NV·Filed 2007·Application pending·0 cites
- 3860US2025179133A1Use of fcrn antagonists for treatment of generalized myasthenia gravisargenx BV·Filed 2025·Application pending·0 cites
- 3957US2017145088A1Humanized antibodiesARGEN-X N V·Filed 2016·Application pending·0 cites
- 4057US2017107302A1Stabilized single domain antibodiesABLYNX NV·Filed 2016·Application pending·0 cites
- 4157US2012251540A1Stabilized single domain antibodiesSILENCE KAREN·Filed 2012·Application pending·0 cites
- 4256US2011178277A1Stabilized single domain antibodiesABLYNX NV·Filed 2011·Application pending·0 cites
- 4352US2011021980A1Needle-free delivery device for therapeutic proteins based on single antigen-binding domains such as nanobodies®ABLYNX NV·Filed 2008·Application pending·0 cites
- 4448US2010113339A1Serum albumin binding proteins with long half-livesABLYNX NV·Filed 2007·Application pending·0 cites
- 4547US2010226920A1Medical delivery device for therapeutic proteins based on single domain antibodiesABLYNX NV·Filed 2007·Application pending·0 cites
- 4646US2007269422A1Serum albumin binding proteins with long half-livesABLYNX NV·Filed 2006·Application pending·0 cites
- 4745US2007178082A1Stabilized single domain antibodiesABLYNX NV·Filed 2003·Application pending·0 cites
- 4836US2016264669A1Methods of reducing serum levels of fc-containing agents using fcrn antagonistsARGEN-X N V·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Torsten Dreier files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →